ProShare Advisors’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-12,797
Closed -$872K 1916
2022
Q3
$872K Buy
12,797
+728
+6% +$40.1K ﹤0.01% 757
2022
Q2
$386K Sell
12,069
-6,255
-34% -$183K ﹤0.01% 1073
2022
Q1
$634K Sell
18,324
-4,285
-19% -$128K ﹤0.01% 1139
2021
Q4
$662K Buy
22,609
+1,603
+8% +$49.7K ﹤0.01% 1273
2021
Q3
$535K Sell
21,006
-5,708
-21% -$168K ﹤0.01% 1172
2021
Q2
$936K Buy
26,714
+18,114
+211% +$707K ﹤0.01% 1077
2021
Q1
$350K Sell
8,600
-937
-10% -$43.1K ﹤0.01% 1697
2020
Q4
$413K Sell
9,537
-352
-4% -$17.4K ﹤0.01% 1392
2020
Q3
$545K Buy
9,889
+153
+2% +$9.72K ﹤0.01% 910
2020
Q2
$615K Sell
9,736
-1,946
-17% -$133K ﹤0.01% 863
2020
Q1
$597K Sell
11,682
-9,195
-44% -$616K ﹤0.01% 696
2019
Q4
$1.66M Sell
20,877
-1,968
-9% -$117K 0.01% 659
2019
Q3
$1.11M Buy
22,845
+711
+3% +$37.1K 0.01% 717
2019
Q2
$1.16M Sell
22,134
-2,821
-11% -$162K 0.01% 710
2019
Q1
$1.32M Buy
24,955
+1,987
+9% +$97.6K 0.01% 694
2018
Q4
$943K Sell
22,968
-4,374
-16% -$164K 0.01% 724
2018
Q3
$1.04M Sell
27,342
-1,018
-4% -$45.1K 0.01% 807
2018
Q2
$1.28M Buy
28,360
+1,620
+6% +$73.8K 0.01% 746
2018
Q1
$1.29M Sell
26,740
-2,283
-8% -$127K 0.01% 740
2017
Q4
$1.14M Buy
29,023
+1,836
+7% +$68.6K 0.01% 776
2017
Q3
$844K Buy
27,187
+1,538
+6% +$43.3K 0.01% 774
2017
Q2
$702K Buy
25,649
+3,827
+18% +$114K 0.01% 838
2017
Q1
$804K Sell
21,822
-5,490
-20% -$138K 0.01% 827
2016
Q4
$395K Buy
+27,312
New +$480K ﹤0.01% 1209

Other funds holding GBT

ProShare Advisors's GBT Position: Q4 2022 in Review

ProShare Advisors sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 12,797 shares — an estimated $872K sold.

ProShare Advisors first reported a position in GBT in Q4 2016 and held it in 24 quarters. The position peaked at $1.66M in Q4 2019. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.

  • ProShare Advisors reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
  • ProShare Advisors sold 12,797 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $872K.
  • ProShare Advisors first reported a position in Global Blood Therapeutics, Inc. in Q4 2016 and held it in 24 quarters.
  • ProShare Advisors's Global Blood Therapeutics, Inc. position peaked at $1.66M in Q4 2019.
  • 2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.

Based on ProShare Advisors's 13F filing for Q4 2022, filed 2 Feb 2023.